Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis

Autor: Hamad Al Ashgar, Hamdan S. Alghamdi, Mohammed A. Babatin, Khaled O Alsaad, Hussa Al Hussaini, Robert P. Myers, Abdulrahman Aljumah, Waleed Al Hamoudi, Khalid I. Bzeizi, Abduljaleel Alalwan, Fayaz A. Handoo, Ayman A. Abdo, Fahad Alsohaibani, Faisal M. Sanai, Hadeel Al Mana, Abeer Ibrahim, Ibrahim Altraif
Rok vydání: 2013
Předmět:
Zdroj: Clinical Gastroenterology and Hepatology. 11:1493-1499.e2
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2013.05.038
Popis: Background & Aims Differing threshold levels of hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) are recommended by international guidelines for commencement of antiviral therapy. These guidelines advocate therapy for patients with significant fibrosis (METAVIR score ≥F2); we assessed the accuracy of these guideline-defined thresholds in identifying patients with ≥F2 fibrosis. Methods We applied the European (European Association for the Study of the Liver [EASL] 2012), Asian-Pacific (Asian-Pacific Association for the Study of the Liver [APASL] 2012), American (American Association for the Study of Liver Diseases [AASLD] 2009), and United States Panel Algorithm (USPA 2008) criteria to 366 consecutive hepatitis B e antigen–negative patients with liver biopsy samples: EASL, ALT >laboratory-defined upper limit of normal (ULN) and HBV DNA ≥2000 IU/mL (n = 171); APASL, ALT >2-fold laboratory-defined ULN and HBV DNA ≥2000 IU/mL (n = 87); AASLD, ALT >2-fold the updated ULN (0.5-fold ULN [corresponding to ≤19 U/L] for women and 0.75-fold the ULN [corresponding to ≤30 U/L] for men) and HBV DNA ≥20,000 IU/mL (n = 53); and USPA, ALT >updated ULN (>0.5-fold ULN for women and >0.75-fold ULN for men) and HBV DNA ≥2000 IU/mL (n = 173). Results Overall, 113 patients (30.9%) had ≥F2 fibrosis, which was more frequent among patients who fulfilled any guideline criteria (45.7% vs 17.9% for those who did not fulfill any criteria, P P = .145) and 82.1%, 73.8%, 77.1%, and 82.4% ( P = .366), respectively. The EASL criteria (area under the receiver operating characteristic [AUROC] curve, 0.66; 95% confidence interval [CI], 0.61–0.71) and USPA criteria (AUROC, 0.66; 95% CI, 0.58–0.73) performed better than APASL (AUROC, 0.64; 95% CI, 0.59–0.69; P = .421) and significantly better than the AASLD criteria (AUROC, 0.59; 95% CI, 0.54–0.64; P = .013). Conclusions In hepatitis B e antigen–negative patients with chronic hepatitis, the EASL, AASLD, APASL, and USPA criteria identify patients with ≥F2 fibrosis with low levels of accuracy. However, the EASL and USPA criteria are the most accurate for identification of these patients.
Databáze: OpenAIRE